Articles tagged with Lung Cancer
A new study has found that worsening depression after diagnosis significantly reduces the survival of lung cancer patients. The trajectory of depressive symptoms was found to be a key factor in understanding how depression relates to premature death. Patients with worsening depression had shorter lifespans, even when receiving advanced...
A Kaiser Permanente study found that the 2021 USPSTF guidelines will likely increase lung cancer screening of women, racial and ethnic minority groups, and individuals with lower socioeconomic status. This is expected to lead to an estimated 30% increase in lung cancer diagnoses compared to the 2013 recommendations.
A phase Ib study found that combining sotorasib, a KRAS G12C inhibitor, with afatinib, a pan-ErbB tyrosine kinase inhibitor, showed antitumor activity in patients with KRAS-mutant non-small cell lung cancer. The combination demonstrated a high disease control rate and improved efficacy compared to prior therapies.
Researchers found that combining an Aurora Kinase A inhibitor with a KRAS inhibitor or WEE1 inhibitor showed efficacy against lung cancer cells resistant to KRAS inhibition. The study suggests that Aurora Kinase A activation contributes to intrinsic and acquired resistance to sotorasib in KRAS-mutated lung cancer cells.
A recent study found that non-Hispanic Black patients who received immunotherapy for advanced-stage non-small cell lung cancer had a lower risk of death compared to non-Hispanic white patients. The researchers controlled for access-related issues and found disparities persisted in certain populations.
Researchers found that older adults with non-small cell lung cancer have low life-space mobility before treatment, which declines after starting treatment. A lower body mass index prior to treatment is associated with an improvement in life-space mobility during treatment.
New studies show that patients with abnormal screening results may face significant out-of-pocket costs for follow-up tests, potentially delaying care. For women, colposcopy costs rose sharply over 13 years, with some facing bills of nearly $1,000. Lung cancer screening CT scans also led to high costs for invasive procedures.
A new analysis suggests that most never-smokers' lung tumors have actionable mutations, making them treatable with existing FDA-approved drugs. The study found that 78-92% of lung cancers in patients who have never smoked can be targeted with precision drugs.
Researchers mapped cancer through protein interactions, revealing biomarkers and potential new treatments for breast and head and neck cancers. The study provides a new definition of biomarkers based on large, multi-protein complexes, offering a more precise way to explain mutation effects.
A new study compared the molecular profiles of lung cancer cells grown in 3D and 2D cultures, finding significant differences in protein expression and regulation. The research used a membrane proteomics approach to analyze the NCI-H23 cell line and identified exclusive expressions of CD molecules in 3D culture.
Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.
The VCU Massey Cancer Center has established a Translational Research Center in Lung Cancer Disparities (TRACER) to address racial disparities in lung cancer. TRACER will investigate the interaction between stress, smoking, and gene expression to raise lung cancer risk in Black men.
A new study found that benzo(a)pyrene plays a small part in the global risk of developing PAH-associated cancer, with 89% of the risk coming from other unregulated chemicals. Degradation products formed in the atmosphere can also be more toxic than the emitted PAHs.
Researchers at Johns Hopkins Kimmel Cancer Center discovered differences in gene activity between immune cells from patients with lung cancer who responded and did not respond to immunotherapies. The findings suggest that non-responders' immune cells can be reprogrammed to act more like responders', potentially leading to new treatment...
A new study finds that racial/ethnic minorities remain less likely to be eligible for lung cancer screening under the revised guidelines, highlighting the need for more nuanced risk models. Incorporating social determinants of health and family history could help address disparities in lung cancer screening eligibility.
Researchers at Weill Cornell Medicine identified club cell factors that inhibit immunosuppressive cells in tumors, leading to increased antitumor T cells and improved effectiveness of PD1 immunotherapy. A
The IMpower010 trial demonstrates that atezolizumab significantly improves disease-free survival in resected, early-stage NSCLC patients compared to best supportive care. Tumors expressing PD-L1 > 50% show a greater benefit of treatment.
A clinical trial found that over half of patients with non-small cell lung cancer (NSCLC) with a HER2 gene mutation had their tumors stop growing or shrink after treatment with trastuzumab deruxtecan. The drug showed durable responses in 54.9% of patients, with median survival period of 17.8 months.
A study identifies four novel subgroups of EGFR mutations that predict drug response, offering a more accurate framework to match patients with targeted therapies. The findings reveal that certain mutations respond better to specific classes of TKIs, providing new clinical opportunities for approved treatments.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
Eosinophils, a type of white blood cell, play a crucial role in destroying malignant tumors by recruiting T-cells and releasing destructive proteins. The study, published in Cancer Research, reveals that eosinophils combat cancer effectively but require the help of T-cells to do so.
The UK Lung Screening Trial (UKLS) found a significant reduction in lung cancer mortality among high-risk groups through low-dose CT screening. The study, which included over 4,000 participants, showed a 16% relative reduction in lung cancer deaths.
A genomic analysis of lung cancer in people with no smoking history identified three molecular subtypes, including the slow-growing 'piano' subtype and the aggressive 'forte' subtype. The study aims to guide clinical treatments based on these subtypes, which may have different prevention and treatment approaches.
A novel AI-powered blood test, DELFI, has been developed to detect lung cancer with high accuracy. The test uses machine learning to analyze cell-free DNA in the bloodstream and has been shown to identify over 90% of patients with lung cancer.
Researchers have developed a prediction model that uses radiomic features from pre-treatment CT scans combined with clinical data to identify patients who are not likely to respond to immunotherapy. The model divides patients into four risk groups, including those with very high and low risks of death following immunotherapy.
A research team from Okayama University has reported the potential of a berry-producing vine, Vitis coignetiae Pulliat (Yamabudo), against lung cancer in mice. The study found that extracts from Yamabudo and its chemical compounds display tumor-suppressing properties by repairing DNA damage and suppressing growth signaling pathways.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
Researchers from UNC School of Medicine, MAHEC, and community partners will address racial disparities in maternal care by improving data accountability and providing community-based doula support. The study aims to decrease pregnancy complications for Black women and improve outcomes in maternal care.
A new therapy, amivantamab, has demonstrated a 40% overall response rate in patients with non-small cell lung cancer and the rare EGFR Ex20Ins mutation. The median duration of response was 11.1 months, offering a potential cure for previously untreatable cases.
The European Respiratory Society has announced the press registration and program for its upcoming International Congress 2021. Over 4,000 presentations on various lung health topics will be presented during the event.
A prospective cohort study found that quitting smoking after being diagnosed with early-stage non-small cell lung cancer can slow disease progression and decrease mortality. Patients who quit smoking lived longer overall, had a longer time to death from lung cancer, and experienced improved survival without cancer recurrence.
A study led by D. Ross Camidge found that MET amplification drives a rare subtype of non-small cell lung cancer, which responded to crizotinib therapy. The research also highlights the importance of MET amplification testing and therapies for this unique patient population.
A study by CNIO researchers found that both isoforms of the KRAS oncogene are oncogenic and must be targeted for therapies to be effective. The research suggests that KRAS4A mutant is even more active than previously thought, inducing lung cancer and metastasis in 20% of individuals.
The study found that AIM2 inflammasome is at the intersection of COPD and lung cancer, with higher expression correlating to lower survival rates in smoking COPD adenocarcinoma patients. This suggests that the AIM2 inflammasome may be a potential target for developing novel treatments for COPD patients who develop lung cancer.
Scientists at Sinai Health discover that all cancers fall into two categories based on the presence or absence of YAP. This binary rule reveals different drug sensitivities and resistance in each classification, offering a new strategy for treating aggressive forms of cancer.
A recent study published in the American Journal of Roentgenology found that reduced-dose CT scans can detect greater than 90% of lung nodules in children and young adults with cancer. This could lead to a reduction in patient dose while maintaining high diagnostic accuracy.
Researchers identified a potential biomarker, A20 protein, that can predict the success of immunotherapy in treating lung cancer. Patients with low A20 expression are less likely to respond to treatment and have poorer survival rates.
Researchers found that MET oncogene amplification creates a hostile environment for immunotherapy, making it ineffective in treating some lung cancers. A combination of a MET inhibitor and anti-PD1 immunotherapy was effective in treating cancers with MET amplification.
A large long-term study found that individuals with high physical activity levels and healthy sleep patterns had lower risks of death from heart disease, stroke, and cancer. Those who were physically inactive and had poor sleep quality were most at risk of dying from these causes.
New research reveals how lung cancer progression disrupts circadian glucose regulation, fueling cancer cell growth. The study identifies REV-ERB? as a key regulator and suggests targeting this protein to suppress cancer cell growth.
A study published in Journal of Thoracic Oncology found that low-dose computed tomography (LDCT) screening for primary lung cancer is associated with a lower risk of developing brain metastases. Researchers identified 1502 participants diagnosed with lung cancer between 2002 and 2009, where LDCT screening was detected versus other meth...
Researchers at Moffitt Cancer Center have developed a non-invasive method to measure PD-L1 biomarker levels in lung cancer patients using PET/CT scan images. This approach uses deep learning to predict checkpoint inhibitor outcomes, which could help determine optimal treatment strategies for patients.
Researchers at Mount Sinai Hospital discovered that early-stage lung cancer tumors hijack immune cells called tissue-resident macrophages to facilitate their invasion of lung tissue. This process allows the tumor to evade the immune system and grow into more deadly stages of cancer.
The LMO1 gene codes for a protein that regulates RNA production and is implicated in cancer formation. Researchers found that overexpression of LMO1 is associated with poor patient outcomes in different cancers. Further study of LMO1 may lead to targeted therapies for various types of cancer.
A modeling study found that schools can reopen safely with controlled community transmission and moderate mitigation strategies in place. Asymptomatic screening is one identified strategy to facilitate reopening while minimizing transmission risk.
The FDA-approved drug sotorasib has been shown to reduce tumor size and improve survival among patients with non-small-cell lung cancer caused by a specific DNA mutation. The study involved 126 patients who showed significant responses to the treatment, including 34% achieving partial response and 3% complete response.
A new study published in the Journal of Thoracic Oncology found that using traditional methods like BMI can misclassify obesity as a non-risk factor for lung cancer. The researchers measured visceral fat index through CT scans and found a clear correlation between central obesity and poor lung cancer outcomes.
A new study found that delaying lung cancer surgery for more than 12 weeks after diagnosis is associated with a higher risk of recurrence and death. Patients who underwent surgery within this time frame lived 7.5 months longer than those who delayed treatment.
The acylfulvene alkylating agent LP-184 demonstrates highly potent anticancer activity in NSCLC cell lines, correlating with PTGR1 transcript levels. It targets tumors regardless of co-occurring mutations but is especially effective in KEAP1 mutant settings.
A new AI algorithm accurately predicts lung cancer risk from low-dose CT scans, outperforming established models and human clinicians. The algorithm may aid in optimizing follow-up recommendations for lung cancer screening participants.
A new study reveals that breast cancer survivors have a 20-44% higher risk of developing new cancer diagnoses compared to healthy individuals. The research identifies specific breast cancer subtypes and diagnosis ages associated with increased risk of subsequent primary cancers.
Research suggests that implementing ATS-recommended air quality standards could prevent tens of thousands of deaths, lung cancer cases, and illnesses. By meeting these standards, the US could avoid an estimated 14,650 deaths, 2,950 lung cancer cases, and 33,000 additional illnesses annually.
A lack of insurance leads to worse cancer survival across the 16 most common cancers, with uninsured patients 60-64 facing significantly poorer outcomes than their older counterparts. This disparity is driven by the high costs of newer potentially lifesaving treatments, which can be unaffordable for those without insurance.
A retrospective study found that CT features can help select patients with stage IA non-small cell lung cancer for sublobar resection. Peritumoral interstitial thickening and pleural contact were independently associated with pathologic lymphovascular invasion, predicting recurrence-free survival after the procedure.
Researchers created a spatial atlas of early-stage lung cancer and normal lung tissue at single-cell resolution, providing insights into tumor development and immune cell interactions. The study identified CD24 as a new immunotherapy target for lung cancer treatment, correlating with poor clinical outcomes and shortened survival.
Researchers found that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening. The study, published in JAMA Network Open, aimed to strengthen the argument for more inclusive guidelines for screening eligibility.
A new study by UCLA researchers identified a novel combination therapy using immune checkpoint inhibitors with ATRA to potentially overcome resistance to immunotherapy in LKB1-deficient lung cancer. The therapy led to eradication of over 70% of tumors and generated durable tumor-specific immunity.
A study by Penn State researchers found that people who felt pleasure in a controversial celebrity's misfortune were less likely to take steps to prevent lung cancer or COVID-19. The study suggests that schadenfreude can demotivate people from taking preventive actions, having serious public health implications.
Researchers at VCU Massey Cancer Center have identified a protein called PLK3 that operates with mutated p53 genes to spur lung cancer growth. Inhibiting PLK3 has been shown to reduce tumor cell formation and proliferation in preclinical models of lung cancer.
Researchers found that patients with high levels of PDL-1 and a KRAS gene mutation lived longer when treated with immunotherapy alone compared to those without the mutation. Patients without the mutation had better survival with combination therapy, suggesting preferred treatment approaches for this patient group.